

CITATION REPORT

List of articles citing

CLINICAL PROOF OF CONCEPT STUDY (BLOSSOM)
SHOWS NOVEL β_3 ADRENOCEPTOR AGONIST YM178
IS EFFECTIVE AND WELL TOLERATED IN THE
TREATMENT OF SYMPTOMS OF OVERACTIVE BLADDER

DOI: 10.1016/s1569-9056(08)60672-7
European Urology Supplements, 2008, 7, 239.

Source: <https://exaly.com/paper-pdf/43899730/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
43	Similarities and differences in the autonomic control of airway and urinary bladder smooth muscle. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2008 , 378, 217-24	3.4	14
42	Investigations into the presence of functional Beta1, Beta2 and Beta3-adrenoceptors in urothelium and detrusor of human bladder. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2009 , 35, 76-83	2	56
41	Effects of beta3-adrenergic receptor activation on rat urinary bladder hyperactivity induced by ovariectomy. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009 , 330, 704-17	4.7	35
40	Prospective pharmacologic therapies for the overactive bladder. <i>Therapeutic Advances in Urology</i> , 2009 , 1, 71-83	3.2	34
39	Editorial comment on: Cizolirtine citrate, an effective treatment for symptomatic patients with urinary incontinence secondary to overactive bladder: a pilot dose-finding study. <i>European Urology</i> , 2009 , 56, 191-2	10.2	1
38	Effect of pre-contraction on β -adrenoceptor-mediated relaxation of rat urinary bladder. <i>World Journal of Urology</i> , 2009 , 27, 711-5	4	33
37	Basic mechanisms of urgency: roles and benefits of pharmacotherapy. <i>World Journal of Urology</i> , 2009 , 27, 705-9	4	17
36	Do gene polymorphisms alone or in combination affect the function of human beta3-adrenoceptors?. <i>British Journal of Pharmacology</i> , 2009 , 156, 127-34	8.6	38
35	Emerging drugs for treatment of urinary incontinence. <i>Expert Opinion on Emerging Drugs</i> , 2010 , 15, 299-308	3.8	4
34	Tissue functions mediated by beta(3)-adrenoceptors-findings and challenges. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2010 , 382, 103-8	3.4	33
33	Detrusor myocyte activity and afferent signaling. <i>Neurourology and Urodynamics</i> , 2010 , 29, 97-106	2.3	75
32	New drug treatments for urinary incontinence. <i>Maturitas</i> , 2010 , 65, 340-7	5	18
31	Correlation between pharmacologically-induced changes in cystometric parameters and spinal c-Fos expression in rats. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2010 , 156, 19-26	2.4	10
30	Physiology and Pharmacology of the Bladder. 2011 , 123-138		
29	β -Adrenergic Receptor Subtypes in the Urinary Tract. <i>Handbook of Experimental Pharmacology</i> , 2011 , 307-18	3.2	21
28	Human atrial β 1L-adrenoceptor but not β 2-adrenoceptor activation increases force and Ca^{2+} current at physiological temperature. <i>British Journal of Pharmacology</i> , 2011 , 162, 823-39	8.6	22
27	Are there functional β -adrenoceptors in the human heart?. <i>British Journal of Pharmacology</i> , 2011 , 162, 817-22	8.6	30

26	Current pharmacotherapy of lower urinary tract symptoms. <i>Surgery</i> , 2011 , 29, 260-264	0.3	3
25	β-adrenoceptor agonist effects in experimental models of bladder dysfunction. <i>Pharmacology & Therapeutics</i> , 2011 , 131, 40-9	13.9	22
24	Desirable properties of β-adrenoceptor agonists: implications for the selection of drug development candidates. <i>European Journal of Pharmacology</i> , 2011 , 657, 1-3	5.3	8
23	The role of antimuscarinics in the management of men with symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an update. <i>European Urology</i> , 2011 , 60, 94-105	10.2	49
22	Urothelial beta-3 adrenergic receptors in the rat bladder. <i>Neurourology and Urodynamics</i> , 2011 , 30, 144-50	5.3	42
21	Use of mirabegron in treating overactive bladder. <i>International Urogynecology Journal</i> , 2012 , 23, 1345-8	2	12
20	β-agonist therapy: a new advance in the management of overactive bladder?. <i>European Urology</i> , 2012 , 62, 841-2	10.2	9
19	Mirabegron: a review of recent data and its prospects in the management of overactive bladder. <i>Therapeutic Advances in Urology</i> , 2012 , 4, 315-24	3.2	70
18	Overactive bladder: diagnosis and management. <i>Maturitas</i> , 2012 , 71, 188-93	5	23
17	Urinary Incontinence: Diagnosis and Treatment in the Elderly. <i>Current Translational Geriatrics and Experimental Gerontology Reports</i> , 2013 , 2, 66-75		7
16	Evidence available on the use of the selective β-adrenoceptor agonist mirabegron for the treatment of overactive bladder. <i>Actas Urológicas Españolas (English Edition)</i> , 2013 , 37, 640-651	0.1	4
15	The medical management of refractory overactive bladder. <i>Maturitas</i> , 2013 , 74, 386-90	5	12
14	Evidence available on the use of the selective β-adrenoceptor agonist mirabegron for the treatment of overactive bladder. <i>Actas Urológicas Españolas</i> , 2013 , 37, 640-51	0.7	9
13	The novel β-adrenoceptor agonist mirabegron reduces carbachol-induced contractile activity in detrusor tissue from patients with bladder outflow obstruction with or without detrusor overactivity. <i>European Journal of Pharmacology</i> , 2013 , 699, 101-5	5.3	34
12	Common theme for drugs effective in overactive bladder treatment: inhibition of afferent signaling from the bladder. <i>International Journal of Urology</i> , 2013 , 20, 21-7	2.3	24
11	Results of a randomized phase III trial of mirabegron in patients with overactive bladder. <i>Journal of Urology</i> , 2013 , 189, 1388-95	2.5	266
10	Expression of β-Adrenoceptor Subtypes in Urothelium, Interstitial Cells and Detrusor of the Human Urinary Bladder. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2013 , 5, 173-80	1.9	12
9	What do we know and not know about mirabegron, a novel β agonist, in the treatment of overactive bladder?. <i>International Urogynecology Journal</i> , 2014 , 25, 165-70	2	13

- 8 Current pharmacotherapy of lower urinary tract symptoms. *Surgery*, **2014**, 32, 292-296 0.3 1
- 7 Antimuscarinic Pharmacotherapy for Overactive Bladder. **2019**, 85-113
- 6 Pharmacologic Management of Lower Urinary Tract Storage and Emptying Failure. **2012**, 1967-2002.e14 3
- 5 Bladder Pharmacology and Treatment of Lower Urinary Tract Symptoms: Recent Advances. *UroToday International Journal*, **2008**, 01, 2
- 4 Pharmacology of the Bladder. **2010**, 212-226
- 3 How Drugs Modify The Micturition Reflex: A Review. *Opticon* **2012**, 7, 9
- 2 Overactive Bladder: Changing Paradigms in Current Guidelines and Pharmacotherapy. *Annals of SBV*, **2017**, 6, 15-20 0
- 1 Pharmacology of Adrenaline, Noradrenaline, and Their Receptors. **2020**, 107-142 0